Literature DB >> 24472799

Results of the ALSTER BP real-world registry on renal denervation employing the Symplicity system.

Lukas Kaiser1, Thomas Beister, Andrea Wiese, Jasper von Wedel, Felix Meincke, Felix Kreidel, Andreas Busjahn, Karl-Heinz Kuck, Martin W Bergmann.   

Abstract

AIMS: To prove the efficacy and safety of renal sympathetic denervation as a new treatment option for patients suffering from resistant hypertension in a real-world setting. METHODS AND
RESULTS: This single-centre real-world registry included 93 patients who underwent renal denervation employing the Symplicity system. Patients were followed for six months. The patient cohort was divided into early responders with a reduction of office systolic blood pressure >10 mmHg three months after the procedure (n=53, 57%), late responders (six months after the procedure, n=16, 17%) and non-responders (n=24, 26%). After six months, systolic blood pressure was lowered by 46±2.9 mmHg (mean±SEM, p<0.001), 31±3.4 mmHg (p<0.001) and 7.1±3.3 mmHg (p=0.79, ns), respectively. Ambulatory blood pressure monitoring also showed a significant reduction in the early responder group (20±5.7 mmHg, p=0.002). We subjected eight patients to a re-do procedure which led to a significant reduction of blood pressure in another five patients after six months (63%). One patient in this cohort developed a one-sided renal artery stenosis associated with an increase in blood pressure.
CONCLUSIONS: This real-world analysis of renal sympathetic denervation confirms the procedure to be safe and efficient in the majority of patients. Non-responders may profit from a second ablation, arguing in favour of the hypothesis that the procedure did not destroy sufficient amounts of sympathetic innervation in these patients. However, repeated denervations may also increase side effects.

Entities:  

Mesh:

Year:  2014        PMID: 24472799     DOI: 10.4244/EIJV10I1A24

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  13 in total

1.  Selective renal denervation guided by renal nerve stimulation: mapping renal nerves for unmet clinical needs.

Authors:  Kunyue Tan; Yinchuan Lai; Weijie Chen; Hang Liu; Yanping Xu; Yidan Li; Hao Zhou; Wenxin Song; Jie Wang; Kamsang Woo; Yuehui Yin
Journal:  J Hum Hypertens       Date:  2019-09-02       Impact factor: 3.012

Review 2.  Device-based therapies for arterial hypertension.

Authors:  Lucas Lauder; Michel Azizi; Ajay J Kirtane; Michael Böhm; Felix Mahfoud
Journal:  Nat Rev Cardiol       Date:  2020-04-14       Impact factor: 32.419

3.  Innervation patterns may limit response to endovascular renal denervation.

Authors:  Abraham R Tzafriri; Felix Mahfoud; John H Keating; Peter M Markham; Anna Spognardi; Gee Wong; Kristine Fuimaono; Michael Böhm; Elazer R Edelman
Journal:  J Am Coll Cardiol       Date:  2014-09-16       Impact factor: 24.094

4.  Resistant hypertension: a therapeutic challenge.

Authors:  Laura Brandani
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-01-05       Impact factor: 3.738

Review 5.  Controversies Surrounding Renal Denervation: Lessons Learned From Real-World Experience in Two United Kingdom Centers.

Authors:  Amy E Burchell; Kenneth Chan; Laura E K Ratcliffe; Emma C Hart; Manish Saxena; David J Collier; Ajay K Jain; Anthony Mathur; Charles J Knight; Mark J Caulfield; Julian F R Paton; Angus K Nightingale; Melvin D Lobo; Andreas Baumbach
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-02-09       Impact factor: 3.738

6.  Blood pressure response to catheter-based renal sympathetic denervation in severe resistant hypertension: data from the Greek Renal Denervation Registry.

Authors:  C Tsioufis; A Ziakas; K Dimitriadis; P Davlouros; M Marketou; A Kasiakogias; C Thomopoulos; D Petroglou; D Tsiachris; M Doumas; E Skalidis; C Karvounis; D Alexopoulos; P Vardas; I Kallikazaros; C Stefanadis; V Papademetriou; D Tousoulis
Journal:  Clin Res Cardiol       Date:  2016-12-12       Impact factor: 5.460

Review 7.  Renal denervation for the management of resistant hypertension.

Authors:  Hitesh C Patel; Carl Hayward; Vassilis Vassiliou; Ketna Patel; James P Howard; Carlo Di Mario
Journal:  Integr Blood Press Control       Date:  2015-12-03

Review 8.  Renal denervation after Symplicity HTN-3: an update.

Authors:  Alexandre Persu; Yu Jin; Fadl Elmula Mohamed Fadl Elmula; Lotte Jacobs; Jean Renkin; Sverre Kjeldsen
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

Review 9.  Chronic Kidney Disease As a Potential Indication for Renal Denervation.

Authors:  Margreet F Sanders; Peter J Blankestijn
Journal:  Front Physiol       Date:  2016-06-08       Impact factor: 4.566

Review 10.  Device-based Therapy for Hypertension.

Authors:  Fu L Ng; Manish Saxena; Felix Mahfoud; Atul Pathak; Melvin D Lobo
Journal:  Curr Hypertens Rep       Date:  2016-08       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.